Supplementary Data Figure S2 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

Abstract

<p>ARX788 activity in HER2-transduced MDA-MB-435 pools. MDA-MB-435 cells transduced with HER2 were sorted into pools with low, medium, and high HER2 expression and quantified for HER2 expression by QiFiKit analysis. Parental MDA-MB-435 cells and the pools were treated with ARX788 for 3 days at 37{degree sign}C, and cell viability was measured.</p>